Cercar
01/10/2024
Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC
Piedra, A, Guinart-Cuadra, A, Mulet, M, Zamora, C, Alejandre, J, Martínez-Recio, S, Barba, A, Sullivan, I, Serra-López, J, Isla, D, Arriola, E, Paz-Ares, L, Diz, MP, Moreno, AL, Callejo, A, Vidal, S, Majem, M. Basal Circulating Leukocyte-Platelet Complexes and PD-L1 Expression on Circulating Cells in Patients with Advanced SCLC. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial)
Provencio, M, Nadal, E, Insa, A, Campelo, MRG, Calvo, V, Palmero, R, Lázaro, M, Dómine, M, Majem, M, Rodríguez-Abreu, D, Martínez-Martí, A, Carpeño, JDC, Cobo, M, Bernabé, R, Viñolas, N, Barneto, I, Viteri, S, Cruz-Bermudez, A, Romero, A, Massutí, B. Five-Year Clinical Outcomes of Perioperative Nivolumab and Chemotherapy in Stage III Non-SmallCell Lung Cancer (NADIM Trial). Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study
Garcia-Campelo, R, Gómez, MD, de Castro, J, Vega, AM, Aix, SP, Arriola, E, Carcereny, E, Majem, M, Vence, GH, González, EE, Pradera, JF, Granados, ALO, Morales, MG, Sureda, BM, Núñez, NF, Provencio, M, González-Mancha, N, Fajardo, CA, Lerones, N, Dols, MC. Patterns of Disease Progression after Atezolizumab Plus Chemotherapy in ES-SCLC: Exploratory Analysis from IMfirst Study. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials
Martínez-Toledo, C, Sierra, B, Molina-Alejandre, M, Casarrubios, M, Calvo, V, Nadal, E, Campelo, MRG, Martínez-Martí, A, Garrido, A, Massutí, B, Insa, A, De Castro, J, Dóomine, M, González-Larriba, JL, Majem, M, Ponce, S, Barneto, I, Aguilar, A, Martín-López, J, Provencio, M, Cruz-Bermúdez, A. TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update
Spigel, DR, Ahn, MJ, Majem, M, Rodríguez, LM, Lee, KH, Carcereny, E, Hernández, AA, Insa, A, Cho, EK, Besse, B, Rha, SY, Weiss, J, D'Arcangelo, M, Im, SA, Kim, SW, Carneiro, BA, Gadgeel, SM, Mitchell, P, Asare, JM, Gainer, SD, Achour, I, Subramaniam, DS, Felip, E. Volrustomig plus platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/10/2024
Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA
Nguyen, D, Besse, B, Cho, BC, Lee, SH, Lee, KH, Lu, S, Cheng, Y, Yao, Y, Girard, N, Lin, CC, Felip, E, Aguilar, A, Charoentum, C, Cruz, FJSM, Majem, M, Lim, CS, Akamatsu, H, Hayashi, H, Yang, JCH, Kowalyszyn, R, Tiscoski, K, Franke, F, Ponomarenko, D, Arslan, C, Forster, M, Urban, D, Misch, D, Delmonte, A, Montes, LVG, Gadgeel, SM, Cruz-Correa, M, Peguero, J, Rousey, S, Gaffar, Y, Owen, S, Schuchard, J, Diels, J, Sermon, J, Sun, T, Ennis, M, Fennema, E, Daksh, M, Sethi, S, Bauml, JM, Campelo, MRG. Amivantamab Plus Lazertinib vs Osimertinib in First Line, EGFR-Mutant Advanced NSCLC: Patientrelevant Outcomes from MARIPOSA. Journal of Thoracic Oncology. 2024; 19(10)DOI:. PMID:. IF:20.800(Q1/1D).
01/09/2024
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study
Rodriguez-Vida, A, Valderrama, BP, Castellano, D, Pinto, A, Mellado, B, Puente, J, Climent, MA, Domenech, M, Vazquez, F, Perez-Gracia, JL, Bonfill, T, Morales-Barrera, R, Gonzalez-Billalabeitia, E, Garcia-del-Muro, X, Maroto, P, Navarro-Gorro, N, Juanpere, N, Juan, O, Bellmunt, J. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. ESMO Open. 2024; 9(9)DOI:10.1016/j.esmoop.2024.103690. PMID:39214051. IF:8.300(Q1/2D).
20/08/2024
Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study
Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study. BMJ-British Medical Journal. 2024; 386DOI:10.1136/bmj-2023-079126. PMID:39164034. IF:42.700(Q1/1D).
15/07/2024
Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Peressini, M, Garcia-Campelo, R, Massuti, B, Marti, C, Cobo, M, Gutiérrez, V, Dómine, M, Fuentes, J, Majem, M, de Castro, J, Córdoba, JF, Diz, MP, Isla, D, Esteban, E, Carcereny, E, Vila, L, Moreno-Vega, A, Ros, S, Moreno, A, García, FJ, Huidobro, G, Aguado, C, Cebey-López, V, Valdivia, J, Palmero, R, Lianes, P, López-Brea, M, Vidal, OJ, Provencio, M, Arriola, E, Baena, J, Herrera, M, Bote, H, Molero, M, Adradas, V, Ponce-Aix, S, Nuñez-Buiza, A, Ucero, A, Hernandez, S, Lopez-Rios, F, Conde, E, Paz-Ares, L, Zugazagoitia, J. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer. CLINICAL CANCER RESEARCH. 2024; 30(14)DOI:10.1158/1078-0432.CCR-24-0104. PMID:38630755. IF:10.200(Q1/1D).
04/07/2024
SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population
Moreno-Cabrera, JM, Feliubadaló, L, Pineda, M, Prada-Dacasa, P, Ramos-Muntada, M, Del Valle, J, Brunet, J, Gel, B, Currás-Freixes, M, Calsina, B, Salazar-Hidalgo, ME, Rodríguez-Balada, M, Roig, B, Fernández-Castillejo, S, Domínguez, M, Ledo, M, Sanz, MI, Castillejo, A, Dámaso, E, Soto, JL, de Miguel, M, Calero, B, Sánchez-Zapardiel, JM, Ramon, T, Lasa, A, Gisbert-Beamud, A, López-Novo, A, Ruiz-Ponte, C, Potrony, M, Alvarez-Mora, M, Osorio, A, Lorda-Sánchez, I, Robledo, M, Cascon, A, Ruiz, A, Spataro, N, Hernan, I, Borràs, E, Moles-Fernández, A, Earl, J, Cadiñanos, J, Sánchez-Heras, AB, Bigas, A, Capellá, G, Lazaro, C. SpadaHC: a database to improve the classification of variants in hereditary cancer genes in the Spanish population. Database-The Journal of Biological Databases and Curation. 2024; 2024DOI:10.1093/database/baae055. PMID:38965703. IF:3.600(Q1/1D).
10/06/2024
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
Gregorc, V, González-Cao, M, Salvagni, S, Koumarianou, A, Gil-Bazo, I, Maio, M, Viteri, S, Majem, M, Gutiérrez, V, Caro, RB, Sanmamed, MF, Zhu, HQ, Shen, HG, Wang, Y, Rosell, R. KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(17_SUPPL)DOI:10.1200/JCO.2024.42.17_suppl.LBA8511. PMID:. IF:41.900(Q1/1D).
01/06/2024
Global cooperation and early access-clinical outcomes matter
Tibau, A, Kesselheim, AS. Global cooperation and early access-clinical outcomes matter. LANCET ONCOLOGY. 2024; 25(6)DOI:10.1016/S1470-2045(24)00210-9. PMID:38754452. IF:35.900(Q1/1D).
01/06/2024
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
Gately, L, Mesía, C, Sepúlveda, JM, del Barco, S, Pineda, E, Gironés, R, Fuster, J, Dumas, M, Gill, S, Navarro, LM, Herrero, A, Dowling, A, de las Peñas, R, Vaz, MA, Alonso, M, Lwin, Z, Harrup, R, Peralta, S, Long, A, Perez-Segura, P, Ahern, E, Garate, CO, Wong, M, Campbell, R, Cuff, K, Jennens, R, Gallego, O, Underhill, C, Martinez-Garcia, M, Covela, M, Cooper, A, Brown, S, Rosenthal, M, Torres, J, Collins, IM, Gibbs, P, Balana, C. Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). JOURNAL OF NEURO-ONCOLOGY. 2024; 168(2)DOI:10.1007/s11060-024-04668-5. PMID:38630385. IF:3.100(Q2/4D).
01/06/2024
Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies
Tibau, A, Hwang, TJ, Avorn, J, Kesselheim, AS. Clinical applicability of guideline-recommended molecular targets and genometargeted cancer therapies. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study
Serda, PC, Cullell, BM, Castet, F, Gatell, AP, Fernandez, PR, Fernandez, J, Nadal, TS, Mateo, FJP, Sorolla, MA, Cajal, TRY. Chemotherapy sensitivity in pancreatic neoplasms with PALB2 Gene mutations: First results of PALB2 pancreatic cancer study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/annonc.2024.05.508. PMID:. IF:65.400(Q1/1D).
01/06/2024
Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study
Reinacher-Schick, AC, Lopez, MR, Alonso-Orduña, V, Lopez-Bravo, DP, Vergauwe, P, Tannapfel, A, Silveira, AB, Schlombs, K, Young, P, He, Y, Henn, H, Manning, L, Preussner, L, Mueller, F, Sahin, U, Türeci, O. Preliminary results correlating post-operative ctDNA status with disease-free survival in patients with stage II (high risk)/III colorectal cancer in the BNT000-001 epidemiology study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024)
Schreurs, MAC, Cajal, TRY, Adank, MA, Collée, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families (vol 73, 103611, 2024). BREAST. 2024; 75DOI:10.1016/j.breast.2024.103723. PMID:. IF:7.900(Q1/1D).
01/06/2024
Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC)
Aggarwal, C, Martinez-Marti, A, Majem, M, Barlesi, F, Carcereny, E, Chu, QS, Monnet, I, Sanchez, A, Dakhil, SR, Camidge, DR, Pillet, M, Brown, M, Dowson, A, Cooper, ZA, Kumar, R, Herbst, RS. Updated results from COAST, a phase 2 study of durvalumab (D) ± oleclumab (O) or monalizumab (M) in patients (pts) with stage III unresectable non-small cell lung cancer (uNSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801
Berciano-Guerrero, MA, Perez-Ruiz, E, Couselo, EM, Manzano, JL, Cerezuela-Fuentes, P, de Miguel, PA, Soria, A, Castaño, AG, Crespo, G, Puértolas, T, De La Rosa, CA, Sanz, LG, Castro, RL, Espinosa, E, Lecumberri, MJ, Majem, M, Martinez, JM, Bellido, L, Fernández-Morales, LA, Martin-Algarra, S. Real-world effectiveness and safety of dabrafenib-trametinib as first-line of treatment for BRAF mutated metastatic melanoma: Results of the study GEM1801. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study
Martelli, V, Barrull, JV, Rodriguez, CF, Alfonso, PG, Paez, D, Gibert, J, Alonso, V, España, MAG, Vivas, CS, Ogalla, GD, Fernandez, MEE, Garcia-Carbonero, R, Monteagudo, RF, Mozo, JLM, Losa, F, Paricio, BB, Tabernero, J, Soler, RS, Aguilar, EA, Viladot, CM. Circulating tumor DNA (ctDNA) to detect acquired resistance to first-line (1L) treatment of RASWT metastatic colorectal cancer (mCRC): Insights from the PLATFORM-B study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.121. PMID:. IF:65.400(Q1/1D).
01/06/2024
Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study
Taieb, J, Fakih, M, Salvatore, L, Esaki, T, Modest, DP, Paez, D, Karamouzis, MV, Ruiz, E, Kim, TW, Kuboki, Y, Meriggi, FA, Cunningham, D, Yeh, KH, Cremolini, C, Wang, J, Tran, Q, Chao, J, Chen, Z, Pietrantonio, F. Patient-reported tolerability of sotorasib (soto) and panitumumab (pani) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in patients (pts) with metastatic colorectal cancer (mCRC) in the CodeBreaK 300 study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.043. PMID:. IF:65.400(Q1/1D).
01/06/2024
Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
John, T, Grohe, C, Goldman, JW, Kato, T, Laktionov, KK, Bonanno, L, Tiseo, M, Majem, M, Domine, M, Ahn, MJ, Perol, M, Hartmaier, R, Robichaux, J, Bhetariya, P, Markovets, A, Rukazenkov, Y, Muldoon, C, Herbst, RS, Tsuboi, M, Wu, YL. Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry
Guerrero, A, Alvarez, I, Novoa, SA, Jurado, JC, Sanchez, CAR, Martinez, P, Falo, C, Hernández-Sosa, M, Margelí, M, Maeso, IG, Rodríguez-Lescure, A, Alcalá, MM, Anton, A, Ferreiro, SV, Herranz, J, Caballero, R, García, DF, Tibau, A, Cobo, SLT, Todo, FGR. Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM/2014-03_RegistEM registry. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas
González-Lopez, JA, Sebio, A, Hindi, N, Jimenez, M, Villarejo-Campos, P, Martin-Broto, J, Díaz-Beveridge, R, Castellanos, JFO, Andújar, RL, Alvarez, RA, Asencio, JM, Serrano, C, Conde, NR, Boix, SC, Gimenez-Salinas, LK, Garcia, JAT, Campos, AP, Lopera, E, Bertran, J, Pousa, AL. First-in-human CEB-01: Novel loco-regional SN-38 release membrane to prevent local recurrence in retroperitoneal sarcomas. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
Garassino, MC, Wakelee, HA, Spicer, J, Liberman, M, Kato, T, Tsuboi, M, Lee, SH, Chen, KN, Dooms, CA, Majem, M, Eigendorff, E, Martinengo, GL, Bylicki, O, Rodriguez-Abreu, D, Chaft, JE, Yang, J, Arunachalam, A, Norquist, JM, Keller, SM, Gao, SG. Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study
Soler, RS, Vivas, CS, Macias, I, Esteban, AY, Bassam, A, Plazas, JG, Al-Farhat, Y, Cervantes, A, Alfonso, PG, Paez, D, Ruiz-Casado, A, Lopez, C, Arkosy, PF, Furka, A, Rodriguez-Salas, N, Pascual, FJR, Gracian, AC, Hitre, E, Monteagudo, RF, Salvia, MAS. Positive ad hoc results from neoadjuvant Foxy-5 treatment of colon cancer patients in the ongoing phase II NeoFox study. ANNALS OF ONCOLOGY. 2024; 35DOI:10.1016/j.annonc.2024.05.020. PMID:. IF:65.400(Q1/1D).
16/05/2024
Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies
Tibau, A, Hwang, TJ, Molto, C, Avorn, J, Kesselheim, AS. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies. JAMA Oncology. 2024; 10(5)DOI:10.1001/jamaoncol.2024.0194. PMID:38573645. IF:20.100(Q1/1D).
01/05/2024
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry
Salazar, J, Garcia-Planella, E, Fernández-Clotet, A, Esteve, M, Gisbert, JP, Busquets, D, Lucendo, A, Márquez, L, Guardiola, J, Martín-Arranz, MD, Iglesias, E, Monfort, D, Villoria, A, Cañete, F, Bell, O, Ricart, E, Zabana, Y, Chaparro, M, Domènech, E, Gordillo, J. Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2024; 90(5)DOI:10.1111/bcp.16017. PMID:38369687. IF:3.000(Q2/4D).
01/05/2024
Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients
Anguera, G, Mulet, M, Zamora, C, Osuna-Gómez, R, Barba, A, Sullivan, I, Serra-López, J, Cantó, E, Vidal, S, Majem, M. Potential Role of Circulating PD-L1+ Leukocytes as a Predictor of Response to Anti-PD-(L)1 Therapy in NSCLC Patients. Biomedicines. 2024; 12(5)DOI:10.3390/biomedicines12050958. PMID:38790920. IF:3.900(Q1/3D).
01/05/2024
Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors
Alserawan, L, Mulet, M, Anguera, G, Riudavets, M, Zamora, C, Osuna-Gómez, R, Serra-López, J, Joaquín, AB, Sullivan, I, Majem, M, Vidal, S. Kinetics of IFN?-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors. Cancers. 2024; 16(9)DOI:10.3390/cancers16091759. PMID:38730712. IF:4.400(Q2/3D).
01/05/2024
Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer
Riudavets, M, Auclin, E, Mosteiro, M, Dempsey, N, Majem, M, Prelaj, A, López-Castro, R, Bosch-Barrera, J, Pilotto, S, Escalera, E, Tagliamento, M, Mosquera, J, Zalcman, G, Nana, FA, Ponce, S, Albarrán-Artahona, V, Dal Maso, A, Spotti, M, Mielgo, X, Mussat, E, Reyes, R, Benítez, JC, Lupinacci, L, Duchemann, B, De Giglio, A, Blaquier, JB, Audigier-Valette, C, Scheffler, M, Nadal, E, Lopes, G, Signorelli, D, Garcia-Campelo, R, Menis, J, Bluthgen, V, Campayo, M, Recondo, G, Besse, B, Mezquita, L, Planchard, D. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2024; 25(3)DOI:10.1016/j.cllc.2023.11.007. PMID:38105153. IF:3.300(Q2/4D).
22/04/2024
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
Torres-Esquius, S, Llop-Guevara, A, Gutiérrez-Enríquez, S, Romey, M, Teulé, A, Llort, G, Herrero, A, Sánchez-Henarejos, P, Vallmajó, A, González-Santiago, S, Chirivella, I, Cano, JM, Graña, B, Simonetti, S, de Corcuera, ID, Cajal, TRY, Sanz, J, Serrano, S, Otero, A, Churruca, C, Sánchez-Heras, AB, Servitja, S, Guillén-Ponce, C, Brunet, J, Denkert, C, Serra, V, Balmaña, J. Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer. JAMA Network Open. 2024; 7(4)DOI:10.1001/jamanetworkopen.2024.7811. PMID:38648056. IF:9.700(Q1/1D).
18/04/2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations
Lubinski, J, Kotsopoulos, J, Moller, P, Pal, T, Eisen, A, Peck, L, Karlan, BY, Aeilts, A, Eng, C, Bordeleau, L, Foulkes, WD, Tung, N, Couch, FJ, Fruscio, R, Cajal, T, Singer, CF, Neuhausen, SL, Zakalik, D, Cybulski, C, Gronwald, J, Huzarski, T, Stempa, K, Dungan, J, Cullinane, C, Olopade, OI, Metcalfe, K, Sun, P, Narod, SA. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations. JAMA Oncology. 2024; DOI:10.1001/jamaoncol.2023.6944. PMID:38421676. IF:20.100(Q1/1D).
10/04/2024
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).
01/04/2024
Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation
Rofes, P, Dueñas, N, del Valle, J, Navarro, M, Balmaña, J, Ramón y Cajal, T, Tuset, N, Castillo, C, González, S, Brunet, J, Capellá, G, Lázaro, C, Pineda, M. Tumor analysis of MMR genes in Lynch-like syndrome: Challenges associated with results interpretation. Cancer Medicine. 2024; 13(7)DOI:10.1002/cam4.7041. PMID:38558366. IF:3.100(Q2/5D).
21/03/2024
The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Rueda, AG, Taus, A, Alvarez, RA, Bernabé-Caro, R, Chara, L, López-Brea, M, Vilà, L, González, MAS, Aldagalán, ADD, Herrera, BE, Castro, RL, Cabellos, RA, Doménech, M, Falagan, S, Vega, AM, Aguado, C, Barba, A, Ureña, MTD, Isla, D, Hernández, LB, Pérez, JLF, Juan-Vidal, O, Massuti, B, Mielgo-Rubio, X, Ortega, AL, Catot, S, Dómine, M, Escoín-Pérez, C, Navalón, FG, Gil-Bazo, I, Muñoz, S, Rodríguez-Abreu, D, Roldán, RMV, Curbera, GA, León-Mateos, L, Padilla, A, Lario, AP, Sánchez-Torres, JM, Garrido, P. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Clinical & Translational Oncology. 2024; 26(9)DOI:10.1007/s12094-024-03404-9. PMID:38512450. IF:2.500(Q3/6D).
01/03/2024
A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)
Di Giacomo, AM, Schenker, M, Medioni, J, Mandziuk, S, Majem, M, Gravis, G, Cornfeld, M, Ranganathan, S, Lou, S, Csoszi, T. A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203). ESMO Open. 2024; 9(3)DOI:10.1016/j.esmoop.2024.102387. PMID:38401247. IF:8.300(Q1/2D).
01/03/2024
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)
Grünwald, V, Powles, T, Eto, M, Kopyltsov, E, Rha, SY, Porta, C, Motzer, R, Hutson, TE, Méndez-Vidal, MJ, Hong, SH, Winquist, E, Goh, JC, Maroto, P, Buchler, T, Takagi, T, Burgents, JE, Perini, R, He, CX, Okpara, CE, McKenzie, J, Choueiri, TK. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023). Frontiers in Oncology. 2024; 13DOI:10.3389/fonc.2023.1343027. PMID:38495081. IF:3.300(Q2/4D).
01/03/2024
What About Variant Histologies in Bladder Cancer?
Day, E, Gavira, J, Tapia, JC, Anguera, G, Maroto, P. What About Variant Histologies in Bladder Cancer?. European Urology Focus. 2024; 10(2)DOI:10.1016/j.euf.2024.05.015. PMID:38849276. IF:5.600(Q1/1D).
01/02/2024
The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families
Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).